The company
CRISPR Therapeutics AG - Common Shares
CRSP · Nasdaq
Health CareGenomics & Gene EditingNot moving yetSynthetic Biology / TechBio
CRSP stood above a rising 150-day average in 13 of the last 52 weekly readings, and has been out of that trend for the last 2 weeks. It is 5.2% below that average now. Genomics & Gene Editing: 20% of its 5 stocks in an uptrend (−40 points in four weeks); Health Care: 26% (−10 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 2
- Industry in uptrend
- 20% -40 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $29.5M
- Officials’ trades on record
- 8
- Institutions holding
- 501 (+31)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 13 of 52 weeks.
20 Apr – 19 Oct
Genomics & Gene Editing: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
1 Nov 2024 – 1 Oct 2026
Open-market buys above the line and sales below, in dollars.
Congress and officials
8 disclosed lines: House 3, Senate 4, executive 1; 4 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| Robert F. Kennedy Executive branch: Office of Government EthicsDepartment of Health and Human Services | sold | $1k–$15k | 4 Apr 2025filed 17 May 2025 |
| Thomas R. Suozzi House: U.S. House ClerkNY03 | sold | $50k–$100k | 20 Sep 2021filed 5 Oct 2021 |
| Thomas R. Suozzi House: U.S. House ClerkNY03 | bought | $50k–$100k | 3 Jun 2021filed 23 Sep 2021 |
| Marjorie Taylor Greene House: U.S. House ClerkGA14 | boughtjoint | $1k–$15k | 21 Jan 2021filed 19 Feb 2021 |
| James M. Inhofe Senate: U.S. Senate eFDSenator | sold part of | $1k–$15k | 5 Jan 2021filed 15 Jan 2021 |
| James M. Inhofe Senate: U.S. Senate eFDSenator | sold part of | $50k–$100k | 22 Dec 2020filed 23 Dec 2020 |
| James M. Inhofe Senate: U.S. Senate eFDSenator | sold part of | $15k–$50k | 19 Jun 2018filed 20 Jun 2018 |
| James M. Inhofe Senate: U.S. Senate eFDSenator | bought | $15k–$50k | 19 Oct 2017filed 8 Nov 2017 |
Insiders
Buy orders, 12 months0
Sale orders, 12 months23
Buyers · sellers0 · 6
| Who | Did | Shares | Traded |
|---|---|---|---|
| Samarth KulkarniChief Executive Officer | sold | 4,098at $49.26 | 14 Oct 2026filed 15 Oct 2026 |
| James R. KasingerGeneral Counsel and Secretary | sold | 1,040at $49.26 | 14 Oct 2026filed 15 Oct 2026 |
| Simeon GeorgeDirector | sold | 14,514at $49.63 | 14 Oct 2026filed 16 Oct 2026 |
| James R. KasingerGeneral Counsel and Secretary | sold | 1,990at $60.04 | 6 Oct 2026filed 8 Oct 2026 |
| James R. KasingerGeneral Counsel and Secretary | sold | 10,400at $60.24 | 22 Sep 2026filed 24 Sep 2026 |
| Ali BehbahaniDirector | sold | 13,679at $57.09 | 17 Sep 2026filed 21 Sep 2026 |
| Naimish PatelChief Medical Officer | sold | 3,786at $55.62 | 29 May 2026filed 1 Jun 2026 |
| Raju PrasadChief Financial Officer | sold | 3,708at $46.78 | 23 Mar 2026filed 24 Mar 2026 |
| Samarth KulkarniChief Executive Officer | sold | 10,020at $46.78 | 23 Mar 2026filed 24 Mar 2026 |
| James R. KasingerGeneral Counsel and Secretary | sold | 3,182at $46.78 | 23 Mar 2026filed 24 Mar 2026 |
| Samarth KulkarniChief Executive Officer | sold | 10,349at $48.26 | 16 Mar 2026filed 17 Mar 2026 |
| James R. KasingerGeneral Counsel and Secretary | sold | 3,450at $48.26 | 16 Mar 2026filed 17 Mar 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Holders501+31 on the quarter
New · exited83 · 51
Reported value$4.1B
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| ARK Investment Management LLCreduced · filed 14 Aug 2026 | 9,460,939$516.0M | -1,852,684−16.4% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 8,348,977$455.4M | +668,904+8.7% |
| Orbis Allan Gray Ltdreduced · filed 14 Aug 2026 | 5,449,161$297.2M | -656,850−10.8% |
| Capital World Investorsadded · filed 12 Aug 2026 | 4,749,525$259.0M | +24,488+0.5% |
| STATE STREET CORPadded · filed 7 Aug 2026 | 4,321,666$235.7M | +339,166+8.5% |
| GSK plcunchanged · filed 13 Aug 2026 | 3,220,627$175.7M | 00.0% |
| GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026 | 2,509,915$136.9M | +132,751+5.6% |
| SR One Capital Management, LPunchanged · filed 12 Aug 2026 | 2,038,763$111.2M | 00.0% |
| TWO SIGMA INVESTMENTS, LPadded · filed 14 Aug 2026 | 1,988,621$108.5M | +505,570+34.1% |
| FMR LLCreduced · filed 13 Aug 2026 | 1,908,503$104.1M | -46,191−2.4% |
31 Mar 2023 – 30 Jun 2026
News
Where Will CRISPR Therapeutics Stock Be in 2030?aol.com · 18 Oct 2026Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.aol.com · 18 Oct 2026Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right.fool.com · 9 Oct 2026CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026manilatimes.net · 8 Oct 2026CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026manilatimes.net · 2 Oct 2026CRISPR Therapeutics Has 2 Key Catalysts Coming by the End of 2026. Is the Market Underestimating Them?fool.com · 29 Sep 2026Crispr Therapeutics: Why AI Giant Anthropic's Discovery Has Rocked Gene Editing (CRSP)seekingalpha.com · 24 Sep 2026CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?fool.com · 24 Sep 2026
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.